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Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma
(HL), but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. We analyzed 131
adults with HL who underwent UCBT in European Society for Blood and Marrow Transplantation centers from 2003
to 2015. Disease status at UCBT was complete remission (CR) in 59 patients (47%), and almost all patients had
received a previous autologous stem cell transplantation. The 4-year progression-free survival (PFS) and overall sur-
vival (OS) were 26% (95% confidence interval [CI], 19% to 34%) and 46% (95% CI, 37% to 55%), respectively. Relapse
incidence was 44% (95% CI, 36% to 54%), and nonrelapse mortality (NRM) was 31% (95% CI, 23% to 40%) at 4 years. In
multivariate analysis refractory/relapsed disease status at UCBT was associated with increased relapse incidence
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2266 A. Paviglianiti et al. / Biol Blood Marrow Transplant 24 (2018) 22652270PFS (HR, 3.45 [95% CI, 1.95 to 6.10], P < .001) and OS (HR, 3.10 [95% CI, 1.60 to 5.99], P = .001). Conditioning regimen
with cyclophosphamide + fludarabine + 2 Gy total body irradiation (Cy+Flu+2GyTBI) was associated with decreased
risk of NRM (HR, .26 [95% CI, .10 to .64], P = .004). Moreover, Cy+Flu+2GyTBI conditioning regimen was associated
with a better OS (HR, .25 [95% CI, .12 to .50], P < .001) and PFS (HR, .51 [95% CI, .27 to .96], P = .04). UCBT is feasible
in heavily pretreated patients with HL. The reduced-intensity conditioning regimen with Cy+Flu+2GyTBI is associ-
ated with a better OS and NRM. However, outcomes are poor in patients not in CR at UCBT.
© 2018 American Society for Blood and Marrow Transplantation.Table 1
Characteristics of Patients (N = 131)
Characteristics Value
Median age at transplantation, yr (range) 29 (18-65)
Median time from diagnosis to UCBT, mo (range) 36 (8-295)
Histologic subtype
Classic, nodular sclerosis 92 (84)
Classic, mixed cellularity 10 (10)
Classic, lymphocyte depletion 2 (2)
Nodular lymphocyte predominant lymphoma 4 (4)












Missing, n = 18
Median time from ASCT to UCBT, mo (range) 16 (2-280)




Missing, n = 6
Median follow-up, mo (range) 55 (4-105)
Values are n (%) unless otherwise defined. CMV indicates cytomegalovirus; PR,
partial remission.INTRODUCTION
Patients with relapsed or primary refractory Hodgkin lym-
phoma (HL) have a dismal prognosis. Intensive chemotherapy
followed by autologous stem cell transplantation (ASCT)
lengthens progression-free survival (PFS). Nevertheless, up to
50% of patients will experience relapse or progression after
this treatment [1].
Allogeneic stem cell transplantation (HSCT) represents a
potentially curative approach for patients who fail ASCT, with
some reports indicating 5-year overall survival (OS) ranging
from 30% to 40% [2,3]. However, the role of HSCT is poorly
defined, albeit the potential graft-versus-lymphoma effect
reported [4]. Furthermore, HL treatment after ASCT is changing
with the emerging use of new therapeutic agents [5-9]. Many
patients cannot benefit from HSCT because they lack a suitable
donor or because of poor performance status. To overcome this
issue, significant changes in practice have occurred in the last
few years. First, the use of alternative donors such as haploi-
dentical family donors has extended the possibility of HSCT for
patients who lack a matched donor [10,11], showing a strong
graft-versus-tumor effect. Second, the advent of reduced-inten-
sity conditioning (RIC) regimens, associated with a decrease in
toxicity and nonrelapse mortality (NRM), has allowed trans-
plantation in patients with poor performance status, which is
often observed in advanced lymphoma [12-15].
The recent use of anti-CD30 monoclonal antibody and anti-
programmed death 1 (anti-PD1) agents has dramatically
improved treatment of patients with HL who relapse after
ASCT or fail previous chemotherapy regimens [16-18]. New
drugs could be used as a bridge to HSCT, allowing patients pre-
viously not fit for this procedure to become eligible when a
response is achieved [19].
To date, limited studies exist on outcomes of patients with
HL undergoing umbilical cord blood transplantation (UCBT)
[11,20].
Hereby, we describe outcomes of 131 patients with HL who
underwent UCBT in Eurocord/European Society for Blood and
Marrow Transplantation (EBMT) centers.
METHODS
Study Design and Inclusion Criteria
This is a retrospective registry-based study using Eurocord/EBMT data.
Patients aged over 18 years and diagnosed with HL who received single or
double UCBT as first allogeneic HSCT in EBMT centers between 2003 and
2015 were included. Patients who received manipulated cord blood or UCBT
associated with other stem cell sources were excluded.
All patients or legal guardians gave informed consent for research. The
study was conducted in accordance with the Declaration of Helsinki. The
Internal Review Board of Eurocord/EBMT approved this study.
Endpoints and Definitions
The primary endpoint was PFS, defined as time from UCBT to relapse,
progression, or death from any cause, whichever occurred first. Secondary
endpoints were neutrophil engraftment, acute and chronic graft-versus-host
disease (GVHD), NRM, relapse incidence (RI), and OS. Neutrophil engraftment
was defined as the first of 3 consecutive days with an absolute neutrophil
count  .5£ 109/L, without evidence of autologous reconstitution. OS was
defined as time from UCBT to death from any cause. Patients alive at last con-
tact or lost to follow-up were censored. RI and NRM were defined as time
from UCBT to relapse and to death without relapse, respectively.A myeloablative conditioning (MAC) regimen was defined as a regimen
containing total body irradiation (TBI) with a dose > 6 Gy, a dose of >8 mg/kg
oral, >6.4 mg/kg i.v. busulfan, or containing >10 mg/kg thiotepa. Acute and
chronic GVHD were evaluated based on standard criteria [21]. The probabili-
ties of PFS and OS were estimated using the Kaplan-Meier method and com-
pared with the log-rank test. Death without an event was treated as a
competing risk to calculate probabilities of neutrophil engraftment and acute
and chronic GVHD. Death without progression or relapse was considered as
competing risk for RI. Relapse was the competing event for NRM.
A P < .05 was considered statistically significant. All variables found to
have P < .10 in the univariate analysis were included in multivariate Cox
models. Type I error was settled at .05. Confidence intervals (CIs) were esti-
mated at 95%. Analyses were performed with SPSS 19 (version 19.0; IBM
SPSS Statistics for Windows, Armonk, NY) and R 3.2.3 (R Foundation for Sta-
tistical Computing, Vienna, Austria) software packages.
RESULTS
Table 1 describes patient characteristics. Most patients
(n = 92, 84%) had nodular sclerosis classic histology. Karnofsky
performance status was 90% in 83 patients (76%).
Disease status at UCBT was complete remission (CR) in 59
patients (47%). Of the 54 patients with available data on the
number of CR, 14 patients were in first CR, 16 were in second
CR, and 24 in third CR.
One hundred twelve patients had a previous ASCT, includ-
ing 19 patients who received 2 previous ASCTs. The median
time from diagnosis to UCBT was 36 months (range, 8 to 295).
Information on treatment received before UCBT was avail-
able for 66 patients. Among these, 31 had Ann Arbor stages III
Table 3
Multivariate Analysis
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at UCBT. Patients received a median of 4 previous chemother-
apy lines (range, 2 to 8), including ASCT. Anti-CD30 or anti-
PD1 was part of the treatment received before UCBT for 22
patients, and 38 underwent radiotherapy before UCBT. After
UCBT 15 patients received anti-CD30 or anti-PD1.
Table 2 shows transplant characteristics. The median number
of total nucleated cells at cryopreservation was 4.08 £ 107/kg
(range, 1.45 to 11.43) for the overall cohort, 3.5 £ 107/kg (range,
1.45 to 6.93) for single UCBT and 4.88 £ 107/kg (range, 2.85 to
11.43) for double UCBT. Conditioning regimen consisted of RIC
for 103 patients (78%), the most common being cyclophospha-
mide +fludarabine + low-dose (2 Gy) TBI (Cy+Flu+2GyTBI)
(n = 71). Cyclosporine A + mycophenolate mofetil was used as
GVHD prophylaxis in 85 patients (65%).
Engraftment and GVHD
One hundred seventeen patients engrafted in a median time
of 18 days (range, 6 to 61). The cumulative incidence of neutro-
phil engraftment at 60 days was 88% (95% CI, 83% to 94%).
Thirty-three patients experienced grades II to IV acute
GVHD in a median time of 28 days (range, 7 to 94). Fifteen
patients had grades III to IV acute GVHD. The cumulative inci-
dence of 100-day acute GVHD grades II to IV was 26% (95% CI,
20% to 35%).
Thirty-three patients developed chronic GVHD in a median
time of 163 days (range, 76 to 935). Fourteen of them had
extensive GVHD. The 4-year cumulative incidence of chronic
GVHD was 32% (95% CI, 24% to 43%). In multivariate analysis
double UCBT was the only factor significantly associated with a
higher risk of aGVHD (HR, 2.89 [95% CI, 1.14 to 7.36], P = .03).
None of the variables tested had a significant impact on







0 to 1 31 (28)
2 80 (72)
Missing, n = 20
Median TNC at cryopreservation, £107/kg (range) 4.08 (1.45-11.43)









CsA + PDN 18 (14)
CsA +MMF 85 (65)
CsA 7 (5)
CsA +MTX 5 (4)
Other 16 (12)
Use of ATG or alemtuzumab
Yes 49 (40)
No 74 (60)
Missing, n = 8
Values are n (%) unless otherwise defined. TNC indicates total nucleated cell at
collection; Bu, busulfan; CsA, cyclosporine A; PDN, prednisone, MMF, myco-
phenolate; MTX, methotrexate; ATG, antithymocyte globulin.RI and NRM
The 4-year cumulative incidence of relapse was 44% (95%
CI, 36% to 54%). Fifty-six patients relapsed after UCBT in a
median time of 6 months (range, .4 to 84). The 4-year NRM
was 31% (95% CI, 23% to 40%).
In multivariate analysis (Table 3) refractory/relapsed dis-
ease status at UCBT was associated with a higher risk of relapse
(HR, 3.14 [95% CI, 1.41 to 7.00], P = .005) and NRM (HR, 3.61
[95% CI, 1.58 to 8.27], P = .002). Conditioning regimen with Cy
+Flu+2GyTBI was associated with decreased risk of NRM (HR,
.26 [95% CI, .10 to .64], P = .004).
Overall, 72 patients died: 31 from relapse, 39 from transplant-
related causes (infection, n = 12; GVHD, n = 8; idiopathic pneumo-
nia syndrome, n = 6; veno-occlusive disease, n = 2; PTLD (post-
transplant lymphoproliferative disorder) Epstein-Barr virus,
n = 2; cardiac toxicity, n = 1; multiorgan failure, n = 3; other
causes, n = 5), and 2 from secondary malignancies.PFS and OS
The median follow-up for survivors was 55 months (range,
4 to 105). The 4-year PFS and OS were 26% (95% CI, 19% to 34%)
and 46% (95% CI, 37% to 55%), respectively (Figures 1 and 2).
According to disease status at the time of UCBT, PFS and OS
were 62% and 38% for patients in CR versus other disease sta-
tus, respectively (Figures 3 and 4) (P < .001).
In multivariate analysis conditioning regimen with Cy+Flu
+2GyTBI was associated with a better OS (HR, .25 [95% CI, .12
to .50], P < .001) and PFS (HR, .51 [95% CI, .27 to .96], P = .04).
Also, refractory/relapsed disease status at UCBT was associatedHR 95% CI P
RI
Double vs. single UCBT .98 .46-2.08 .95
Median year of UCBT > 2010 vs. 2010 1.31 .73-2.37 .37
Disease status at UCBT
CR ref
PR 1.90 .95-3.80 .07
Relapsed/refractory 3.14 1.41-7.00 .005
Conditioning intensity (RIC vs. MAC) .75 .29-1.95 .55
Cy+Flu+2GyTBI vs. other chemotherapy regimen .98 .38-2.53 .97
NRM
Double vs. single UCBT 1.20 .52-2.77 .67
Median year of UCBT > 2010 vs. 2010 .99 .50-1.97 .97
Disease status at UCBT
CR ref
PR 1.20 .50-2.92 .69
Relapsed/refractory 3.61 1.58-8.28 .002
Conditioning intensity (RIC vs. MAC) 1.30 .57-2.98 .54
Cy+Flu+2GyTBI vs. other chemotherapy regimen .26 .10-.64 .004
PFS
Double vs. single UCBT 1.12 .63-1.97 .70
Median year of UCBT > 2010 vs. 2010 1.14 .73-1.79 .55
Disease status at UCBT
CR ref
PR 1.57 .91-2.71 .10
Relapsed/refractory 3.45 1.95-6.10 <.001
Conditioning intensity (RIC vs. MAC) 1.04 .56-1.93 .91
Cy+Flu+2GyTBI vs. other chemotherapy regimen .51 .27-.96 .04
OS
Double vs. single UCBT 1.19 .64-2.24 .58
Median year of UCBT > 2010 vs. 2010 .90 .53-1.52 .68
Disease status at UCBT
CR ref
PR 1.78 .94-3.34 .08
Relapsed/refractory 3.10 1.6-5.99 .001
Conditioning intensity (RIC vs. MAC) 1.22 .62-2.4 .56
Cy+Flu+2GyTBI vs. other chemotherapy regimen .25 .12-.50 <.001
Figure 1. Four-year PFS (progression free survival) of the entire cohort .
Figure 2. Four-year OS (overall survival) of the entire cohort.
Figure 3. Four-year PFS according to disease status for patients in CR (solid line)
and for patients in relapsed/refractory or partial remission (dashed line).
Figure 4. Four-year OS according to disease status for patients in CR (solid line)
and for patients in relapsed/refractory or partial remission (dashed line).
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OS (HR, 3.10 [95% CI, 1.60 to 5.99], P = .001).
DISCUSSION
This study reports 1 of the largest series of HL patients
given UCBT. To date, there are limited studies in this settings,
with few patients reported [20,22-26].
Brunstein et al. [20] described 65 patients with lymphoproli-
ferative disease, 23 with HL, receiving UCBT with Cy+Flu+2Gy
TBI as conditioning regimen. The 3-year PFS and OS for patients
with HL were 33% and 43%, respectively, and the 3-year NRM
was 13%. The Eurocord and EBMT Lymphoma Working Party
reported a 1-year PFS of 40% and 1-year OS of 48% for adult
patients with lymphoma (n = 104, 29 with HL) who underwent
either RIC or MAC UCBT. For patients receiving RIC (n = 64), theconditioning regimen was Cy+Flu+2GyTBI in 42 cases. In this
study patients who received low-dose TBI had better OS and
PFS and lower NRM in the multivariate analysis [24]. Thompson
et al. [26] showed the results of 27 patients with HL undergoing
UCBT with RIC and MAC regimens, with a 5-year PFS, RI, and
NRM of 31%, 38%, and 26%, respectively. Our results are in line
with previous reports, supporting these findings in a more com-
prehensive and uniform cohort of patients who received UCBT.
Data on treatment before UCBT were available for 66 patients,
with a median number of previous chemotherapy lines of 4 in
this subgroup. Although we cannot attribute this result to the
entire study cohort, this may indicate a tendency for a population
composed of heavily treated patients who had at least 1 previous
ASCT in almost all cases, which is consistent with the use of HSCT
from alternative donors in this setting.
Our analysis showed that disease status at the time of UCBT
is 1 of the most important factors impacting mortality, disease
recurrence, PFS, and OS. The detrimental effect of disease sta-
tus has been reported by Marcais et al. [22] in HL patients who
A. Paviglianiti et al. / Biol Blood Marrow Transplant 24 (2018) 22652270 2269underwent HSCT from identical sibling or unrelated donors
using bone marrow (n = 24), peripheral blood stem cells
(n = 149), or cord blood (n = 17) as the stem cell source. Also,
disease status at transplantation was the only risk factor asso-
ciated with lower OS for 98 adult HL patients undergoing RIC
HSCT from alternative donors (matched unrelated donor,
n = 27; nonT celldepleted haploidentical with post-trans-
plant cyclophosphamide [HAPLO PTCy], n = 34; cord blood,
n = 37) [11]. In this retrospective analysis, outcomes were not
significantly different among recipients of cord blood, HAPLO
PTCy, and matched unrelated donor in terms of RI, NRM,
event-free survival, and OS [11]. These findings, together with
our results, further support the importance of disease control
before HSCT for HL patients, regardless of donor source.
We reported an NRM of 31% at 4 years, which is consistent
with a heavily pretreated cohort of patients, some of whom
(20%) transplanted after a MAC regimen. Similar results have
been reported in other studies, including UCBT with RIC and
MAC regimens [24-26]. In contrast, Brunstein et al. [20] and
Gauthier et al. [11] reported lower rates of NRM (13% and
11%). This may be due to the inclusion of younger and less pre-
viously treated cohorts (almost all patients received less than 4
chemotherapy lines before HSCT) and of only RIC HSCT in both
studies [11,20]. Importantly, we found a significant decrease in
NRM for patients who received the Cy+Flu+2GyTBI (19% at
4 years) conditioning regimen. Furthermore, the results of the
phase II study HDR-Allo trial with 92 advanced HL patients
who underwent RIC HSCT corroborate our findings with an
NRM of 17% at 2 years [15].
Previous reports demonstrated no difference in outcomes for
advanced HL patients undergoing RIC using either UCBT (n = 9)
or matched sibling donors (n = 12), although in a limited cohort
[23]. More recently, Bachanova et al. [10] reported comparable
outcomes in a large cohort of 1593 advanced lymphoma
patients (346 with HL) transplanted with matched related
donors, 7/8mismatched unrelated, and cord blood. These results
highlight the acceptable survival rate after alternative donor
transplantation, extending the benefit of allogeneic transplant
to patients with HLwho lack an HLA-matched donor.
The use of other alternative donor transplants, such as
HAPLO PTCy, is increasing over the years. Few studies have
reported encouraging results for HAPLO PTCy in advanced HL
with PFS ranging from 59% to 63% and OS from 63% to 77%
[27,28]. More recently, HAPLO PTCy outcomes have been com-
pared with HLA-identical sibling HSCT from 2 transplant cen-
ters, showing a reduced 3-year RI for HAPLO PTCy [29]. Also, in
a limited cohort of patients with lymphoproliferative disease
(HL = 9) who received more than 3 lines of prior treatment,
combined CD34-selected haploidentical grafts with cord blood
showed a PFS and OS of 73% and 86% at 1 year, respectively,
supporting this treatment as a promising option [30].
The place of UCBT in the setting of relapsed/refractory HL
should be carefully considered also in view of the increasing
use of HAPLO PTCy transplant [31]. In the case of impossibility
of donor lymphocyte infusion the use of new agents may be a
suitable therapeutic option for patients with HL who relapse
after UCBT. The use of novel agents has been recently
explored in relapsed/refractory HL in association with benda-
mustine demonstrated to be a safety alternative to platinum-
based chemotherapy before ASCT [32]. The possible applica-
tion of this therapeutic option also as post-transplant mainte-
nance should be evaluated further in clinical trials. New drugs
could be used to improve response strength before UCBT or in
maintenance after transplantation, as suggested for consoli-
dation after ASCT per the AETHERA study [33]. In thisrandomized study anti-CD30 was used versus placebo after
ASCT with a benefit in PFS.
Some reports have investigated the use of novel agents in
the allogeneic setting [6,7,34]. Bazarbachi et al. [34] retrospec-
tively compared outcomes of 210 patients who received anti-
CD30 before HSCT to 218 patients who did not, and this was
not associated with different outcomes between the 2 cohorts.
Merryman et al. [35] reported 39 patients receiving anti-PD1
infusion before HSCT, with a higher than expected incidence of
veno-occlusive disease (n = 3) and a 1-year cumulative inci-
dence of grade IV acute GVHD of 13%.
More cases with longer follow-up are needed to better
define the algorithm of UCBT for HL in view of new drugs cur-
rently available in clinical trials.
We are aware that some unmeasured factors may not have
been considered, such as pretransplant-specific disease charac-
teristics and anti-PD1 or CD30 use before or after UCBT that
may have impacted our results. The inability to consider all fac-
tors is a common limitation in retrospective analyses. Never-
theless, our study remains of value because it is 1 of the largest
reports describing UCBT in patients with HL.
In conclusion, UCBT is a feasible alternative for patients with
HL. When considering this donor source, a RIC regimen with
low-dose TBI has showed encouraging results and is effective in
reducing toxicity and mortality. The use of novel agents, as both
a bridge to transplant and maintenance treatment, needs to be
further investigated in prospective clinical studies.
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